Search Results - "Fischel, J. L."

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model by Bozec, A., Sudaka, A., Toussan, N., Fischel, J.-L., Etienne-Grimaldi, M.-C., Milano, G.

“…Recent preclinical and clinical studies indicate beneficial effects from combining radiotherapy with either anti-angiogenic drugs or anti-epidermal growth…”
Get full text

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity by Beauclair, S, Formento, P, Fischel, JL, Lescaut, W, Largillier, R, Chamorey, E, Hofman, P, Ferrero, JM, Pagès, G, Milano, G

“…Background: To examine the impact of a frequent her2 gene polymorphism (Ile655Val) on tumor growth and on the pharmacodynamics of treatment by trastuzumab…”
Get full text

Pharmacological background of EGFR targeting by Castillo, L., Etienne-Grimaldi, M. C., Fischel, J. L., Formento, P., Magné, N., Milano, G.

“…Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. As a…”
Get full text

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors by Fischel, J-L, Formento, P, Milano, G

“…Among the recent advances in the molecular targeted therapy of cancer, the applications focused on epidermal growth factor receptor (EGFR) are currently the…”
Get full text

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity by ETIENNE, M-C, IIC, K, FORMENTO, J-L, LAURENT-PUIG, P, FORMENTO, P, CHERADAME, S, FISCHEL, J-L, MILANO, G

“…The relationship of thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms on 5-fluorouracil (FU) sensitivity was tested…”
Get full text

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin 5-fluorouracil by MAGNE, N, FISCHEL, J.-L, MILANO, G, TIFFON, C, FORMENTO, P, DUBREUIL, A, PENEE, N, FORMENTO, J.-L, FRANCOUAL, M, CICCOLINI, J, ETIENNE, M.-C

“…ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently being investigated in clinical…”
Get full text

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126 by BOZEC, A, LASSALLE, S, GUGENHEIM, J, FISCHEL, J.-L, FORMENTO, P, HOFMAN, P, MILANO, G

“…Current experimental and clinical knowledge supports the optimisation of endothelial cell targeting using a strategy combining anti-EGFR drugs with…”
Get full text

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer by Guérin, O., Formento, P., Lo Nigro, C., Hofman, P., Fischel, J. L., Etienne-Grimaldi, M. C., Merlano, M., Ferrero, J. M., Milano, G.

“…Purpose Physiological and molecular findings indicate over-expression of HER proteins and dysregulation of neo-angiogenesis during progression of advanced…”
Get full text

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer by MAGNE, N, FISCHEL, J. L, DUBREUIL, A, FORMENTO, P, MARCIE, S, LAGRANGE, J-L, MILANO, G

“…Elevated levels of epidermal growth factor receptor in head and neck cancer have been extensively reported, and are correlated with poor prognosis. The…”
Get full text

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity by Etienne, M C, Chéradame, S, Fischel, J L, Formento, P, Dassonville, O, Renée, N, Schneider, M, Thyss, A, Demard, F, Milano, G

“…The aim of the present study was to analyze the role of thymidylate synthase (TS; main cellular target of fluorouracil [FU]) and dihydropyrimidine…”
Get more information

Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines by Chefrour, M., Fischel, J.-L., Formento, P., Giacometti, S., Ferri-Dessens, R.-M., Marouani, H., Francoual, M., Renée, N., Mercier, C., Milano, G., Ciccolini, J.

“…The combination of capecitabine and the tyrosine kinase inhibitor erlotinib has recently been tested in patients with gemcitabine-refractory pancreatic tumors,…”
Get full text

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines by Fischel, J L, Rostagno, P, Formento, P, Dubreuil, A, Etienne, M C, Milano, G

“…A marked antitumour efficacy is currently obtained by oxaliplatin (LOHP)-fluorouracil (FU)-folinic acid (FA) combination and by CPT11-FU-FA combination…”
Get full text

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity by FISCHEL, J. L, FORMENTO, P, CICCOLINIL, J, ROSTAGNO, P, ETIENNE, M. C, CATALIN, J, MILANO, G

“…The combination of 5-fluorouracil-folinic acid and oxaliplatin has led to a significant improvement of chemotherapy efficacy in advanced pretreated colorectal…”
Get full text

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data by FISCHEL, J.-L, ETIENNE, M.-C, FORMENTO, P, MILANO, G

“…The combination of oxaliplatin (LOHP)-5-fluorouracil (FU)-folinic acid (FA) has provided high response rates in pretreated patients with advanced colorectal…”
Get full text

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil by Beck, A, Etienne, M C, Chéradame, S, Fischel, J L, Formento, P, Renée, N, Milano, G

“…Despite being one of the oldest anti-cancer drugs, fluorouracil (FU) is still being increasingly used in cancer chemotherapy. The source of variability for FU…”
Get more information

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model by Bozec, A, Sudaka, A, Fischel, J-L, Brunstein, M-C, Etienne-Grimaldi, M-C, Milano, G

“…Clinical benefit has been demonstrated in patients with head and neck tumours receiving an anti-epidermal growth factor receptor (EGFR) agent in combination…”
Get full text

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation by FISCHEL, J. L, ETIENNE, M. C, SPECTOR, T, FORMENTO, P, RENEE, N, MILANO, G

“…Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme of 5-fluorouracil (FU) catabolism. Ethynyluracil (776C) is a very potent, mechanism-based…”
Get full text

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis by MARCHETTI, S, CHAZAL, M, DUBREUIL, A, FISCHEL, J. L, ETIENNE, M. C, MILANO, G

“…Tumoral thymidine phosphorylase (TP) appears to play a dual role by being involved in neoangiogenesis and by activating 5FU prodrugs at the tumoral target…”
Get full text

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa') by Magné, N, Fischel, J L, Dubreuil, A, Formento, P, Poupon, M-F, Laurent-Puig, P, Milano, G

“…of ZD1839 ("Iressa") is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), which blocks signal transduction…”
Get full text

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: Experimental data by Chéradame, S., Etienne, M.-C., Chazal, M., Guillot, T., Fischel, J.-L., Formento, P., Milano, G.

“…The purpose of this study was to investigate folate-related predictors of 5-fluorouracil (5-FU) cytotoxiticy in the presence or absence of l-folinic acid (…”
Get full text